Qizheng Tibetan medicine: promoting phase II clinical work of new anticancer drug ethane Selene

Qizheng Tibetan medicine said that recent rumors about the company's new anti-cancer drugs are inconsistent with the facts At present, the company and Peking University are promoting phase II clinical work It is rumored that the first phase clinical effect of Qizheng Tibetan medicine is not ideal, and Peking University has dissolved the working group of the project In this regard, some investors ask the company to verify whether it is true on the above platform Qizheng Tibetan medicine is mainly engaged in the research and development, production and sales of Tibetan medicine, including external painkillers, oral medicine, etc In 2009, ethane Selene, a cancer drug jointly developed by Peking University and Gansu Qizheng Tibetan Medicine Co., Ltd., obtained the clinical approval issued by the State Food and Drug Administration and entered the first phase of clinical research This is an innovative drug with completely independent intellectual property rights and used to treat tumors, which is originally innovated by Chinese scientists, protected by a number of domestic invention patents, and has applied for international patent protection At present, a series of studies have been completed, which show that ethane Selene can inhibit lung cancer, colon cancer, gastric cancer and other tumors Background of the research and development team: Zeng Huihui, Ph D professor and doctoral supervisor of the school of medicine, Peking University, State Key Laboratory of natural and bionic drugs, pi - person in charge of selenium drug research office, email: zenghh@bjmu.edu.cn personal profile In 1986, he received a master's degree from the Department of chemistry, Wuhan University; in 1994, he received a doctor's degree in pharmaceutical chemistry from the school of pharmacy, Peking University; in 1998-1999, he received a postdoctoral degree from the Department of pharmacology, School of medicine, Seoul University, South Korea; since 1986, he has been an assistant professor, lecturer and associate professor in the Department of chemical biology, School of pharmacy, Peking University Mainly engaged in: new drug research, anticancer drug mechanism research From 1999 to now, he has been in charge of all preclinical research and development of the innovative anti-tumor drug ethane Selene He is the general director of the team of ethane Selene research and development center authorized by Peking University legal person He has successfully presided over and completed the preclinical research and development of the innovative anti-tumor drug ethane Selene He has been in charge of organizing clinical application He is also the general writer of the drug ind document and the general director of the document In 2007, it was approved by SFDA for two clinical approvals of class I chemicals (approval No.: 2007l047382007l04741) He is the technical requirements representative of the applicant for clinical research of the innovative drug ethane Selene dispersible tablet and the general director of non clinical research technical support In 2009, it obtained 2 projects of national major new drug varieties The new drug research project was selected into the "15211" program of Peking University Beijing Municipal Commission of science and technology quickly tracks key chemical innovative drugs As the first inventor, it has applied for 11 Chinese invention patents, including 6 authorized patents As the first inventor of drugs, it has applied for international patent protection of drugs in 24 countries, including the United States, Europe, Japan, Russia and Canada, among which Russia has already obtained Russia One authorized by Sri Lanka and one authorized by the United States He is the inventor of a number of domestic and international invention patents for the innovative anti-tumor drug ethane Selene He has established the theoretical system of the innovative drug ethane Selene and organized the research team to publish more than 50 research series on the innovative drug ethane Selene at home and abroad The research on the theoretical system of the first drug ethane Selene targeted at thioredoxin reductase inhibitor has attracted wide international attention Among them, the first article has been cited positively by many important international publications such as chem Rev., JBC, minerals in cancer biology, mini reviews in medical chemistry and NCI research work in the United States 2008 Beijing Science and Technology Award for the first adult